ALung Initiates Enrollment in Pivotal Trial of the Hemolung RAS for the US Market

ALung Technologies recently announced the initiation of patient enrollment in its VENT-AVOID trails with the Minneapolis Heart Institute Foundation. The trial is pivotal in validating the safety and efficacy of the Hemolung Respiratory Assist System for COPD patients who require ventilatory support.

Learn more about ALung’s announcement here.